Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) emerged as the highest-selling new drug in India in 2024, generating Rs 58 ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.